Condition
Enteropathy Associated T Cell Lymphoma
Total Trials
3
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
P 2 (2)
P 4 (1)
Trial Status
Unknown2
Not Yet Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT06701344Phase 2Not Yet RecruitingPrimary
Go-CHOP in de Novo Intestinal T-cell Lymphoma Patients
NCT02533700Phase 2Unknown
CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL
NCT01746992Phase 4Unknown
CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma
Showing all 3 trials